By design, the drug development process may seem overly complex, involving many teams that bring varied experience and expertise as they all drive research forward toward the goal of bringing an innovative new therapy to market and to the patients who stand to benefit from it. This approach – seen more as a qualitative process – typically includes a combination of clinical and non-clinical development teams, as well as medical affairs teams and epidemiologists who bring in real-world evidence and the patient experience. In the above video, Mat Davis, PhD, Vice President, Head of Data Science, Evidence and Value Generation defines quantitative drug development and discusses how Jazz takes a different approach to the more traditional, and often more siloed, qualitative process, one that harnesses quantitative processes and centers on real-world data to bring forward the maximum benefit for patients.
Simplifying the drug development process by leveraging focused and integrated quantitative methods is just one of the ways Jazz is innovating to transform the lives of patients. What makes us unique in the pharmaceutical industry is how we have centralized many of the data science functions into one department, breaking down the silos to fully embrace the value of data science and removing the barriers to drug development.
To learn more, click here to watch Mat Davis share insights on Jazz’s perspective on quantitative drug development at the 2023 STAT Eureka Conference. Mat also shared additional insights on the unique processes at Jazz on The Effective Statistician podcast. Listen here.
